Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.

@article{Uwagawa2009CombinationCO,
  title={Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.},
  author={Tadashi Uwagawa and Paul J. Chiao and Takeshi Gocho and Shouichi Hirohara and Takeyuki Misawa and Katsuhiko Yanaga},
  journal={Anticancer research},
  year={2009},
  volume={29 8},
  pages={
          3173-8
        }
}
PURPOSE Gemcitabine is currently the standard first-line chemotherapeutic agent for pancreatic cancer. However, chemoresistance to gemcitabine because of gemcitabine-induced nuclear factor-kappaB (NF-kappaB) activation has been reported. We previously reported that the synthetic serine protease inhibitor nafamostat mesilate inhibited NF-kappaB activation and induced apoptosis of pancreatic cancer cells. In this study, whether or not nafamostat mesilate could enhance the anticancer effect of… CONTINUE READING
Highly Cited
This paper has 43 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.

The Journal of surgical research • 2016
View 4 Excerpts
Highly Influenced